NCT01932528View on ClinicalTrials.gov

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2013

Conditions
Carcinoid Syndrome
Interventions
DRUG

500 mg [14C]-LX1606

500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.

Trial Locations (1)

NG11 6JS

Lexicon Investigational Site, Nottingham

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY